Why this EMEA contract matters for Cognyte Software (CGNT)
Cognyte Software (NasdaqGS:CGNT) drew fresh attention after securing a three year subscription contract in the EMEA region worth over US$20 million, extending a long standing relationship with a government agency client.
See our latest analysis for Cognyte Software.
The contract news lands during a period of strong momentum, with a 45.39% 90 day share price return and a 30 day share price return of 21.08%, while the three year total shareholder return of 159.07% contrasts with a five year total shareholder return that declined by 54.89%.
If this AI driven contract has you thinking about what else is moving, it could be a good moment to scan 64 profitable AI stocks that aren't just burning cash as potential next ideas.
With revenue of about US$400 million, a recent loss, and the stock trading around US$10.57 at an apparent discount to some intrinsic estimates and analyst targets, the question is whether there is still an opportunity to invest or if the market is already pricing in future growth.
Most Popular Narrative: 89% Undervalued
Against a last close of $10.57, the most followed narrative on Cognyte places fair value at $95.67, which implies a very wide valuation gap that hinges on aggressive growth and margin assumptions.
The Path to 2031: An Optimistic Scenario
Here’s where it gets exciting. Let me map out a realistic but optimistic trajectory:
Revenue Growth Path:
∙ FY26 (ending Jan 2026): ~$400M (confirmed guidance)
∙ FY28 (ending Jan 2028): ~$500M (management’s stated target)
∙ FY29 to FY31: If the US market takes off via LexisNexis and organic growth, and international contracts continue compounding, a 15% to 20% annual growth rate is achievable
∙ By FY31 (ending Jan 2031): $750M to $1B in revenue
Margin Expansion:
∙ EBITDA margins are already expanding rapidly (from single digits to ~12% and climbing)
∙ As the subscription model scales and the US market generates higher-margin software revenue, EBITDA margins of 20% to 25% are realistic by 2031
∙ That implies $150M to $250M in EBITDA
Multiple Expansion:
∙ At $400M revenue today, Cognyte trades at ~1.5x revenue
∙ As the company proves its US growth story, transitions further to SaaS, and approaches profitability, a re-rating to 5x to 8x revenue is not unreasonable (still a fraction of Palantir’s multiple)
∙ Government analytics companies with proven growth and recurring revenue routinely trade at 6x to 10x revenue
TheValueDetector is effectively pricing in a shift to much higher recurring revenue, stronger EBITDA margins and a richer future sales multiple, all working together to justify that $95.67 fair value without changing the current loss making status.
Result: Fair Value of $95.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the stock is still loss making and heavily reliant on government contracts, so contract delays or weaker order activity could quickly challenge this optimistic narrative.
Find out about the key risks to this Cognyte Software narrative.
Next Steps
If this mix of optimism and risk feels finely balanced, do not wait for a consensus. Go through the details yourself and weigh the 3 key rewards.
Ready to uncover more investment ideas?
If Cognyte has sharpened your interest, do not stop here, the next opportunity you miss could be the one that fits your portfolio best.
- Target quality at a discount by scanning 44 high quality undervalued stocks that combine solid fundamentals with pricing that may not fully reflect their potential.
- Strengthen your portfolio’s foundations by reviewing solid balance sheet and fundamentals stocks screener (45 results) that prioritise financial resilience and disciplined balance sheet management.
- Get ahead of the crowd by focusing on screener containing 23 high quality undiscovered gems before they appear on every investor’s radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com